デフォルト表紙
市場調査レポート
商品コード
1004979

多形性膠芽腫の世界市場(2020年~2027年)

Glioblastoma Multiforme Market -2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 207 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
多形性膠芽腫の世界市場(2020年~2027年)
出版日: 2021年05月12日
発行: DataM Intelligence
ページ情報: 英文 207 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の多形性膠芽腫市場では、免疫療法による多形性膠芽腫の治療研究と臨床試験の増加しており、予測期間(2020年~2027年)に高いCAGRで成長すると予測されています。主な成長要因には、脳やその他の神経系のがんの増加、クローズドエンド型投資企業による資金提供の増加、有望なパイプライン薬、および新薬に対する米国FDAの承認の増加などが挙げられます。

当レポートは、世界の多形性膠芽腫市場について調査しており、市場の機会や影響、成長および抑制要因、治療タイプ・分子タイプ・投与経路・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 多形性膠芽腫市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 多形性膠芽腫市場-市場の定義と概要

第3章 多形性膠芽腫市場-エグゼクティブサマリー

  • 治療タイプ別の市場内訳
  • 分子タイプ別の市場内訳
  • 投与経路別の市場内訳
  • エンドユーザー別市場内訳

第4章 多形性膠芽腫の市場力学

  • 市場に影響を与える要因
  • 成長要因
    • 多形性膠芽腫の発生率の上昇
    • 有望なパイプライン薬
  • 抑制要因
    • 多形性膠芽腫の再発
  • 市場機会
  • 影響分析

第5章 多形性膠芽腫市場-業界分析

  • ポーターのファイブフォース分析
  • 規制分析
  • サプライチェーン分析
  • 価格分析
  • アンメットニーズ

第6章 多形性膠芽腫市場-治療タイプ別

  • イントロダクション
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • 治療タイプ別の市場魅力指数
  • 薬剤
    • イントロダクション
    • 市場規模分析、および前年比成長分析(2018-2026)
    • テモゾロミド
    • ベバシズマブ
    • カルムスチン
    • その他
  • 免疫療法
  • 電界療法
  • その他

第7章 多形性膠芽腫市場-分子タイプ別

  • イントロダクション
    • 分子タイプ別:市場規模分析、および前年比成長分析
    • 分子セグメント別:市場魅力指数
  • 低分子
    • イントロダクション
    • 市場規模分析、および前年比成長分析(2018-2026)
  • 生物製剤

第8章 多形性膠芽腫市場-投与経路別

  • イントロダクション
    • 投与経路別:市場規模分析、および前年比成長分析
    • 投与経路セグメント別:市場魅力指数
  • 経口
    • イントロダクション
    • 市場規模分析、および前年比成長分析(2018-2026)
  • 非経口

第9章 多形性膠芽腫市場-エンドユーザー別

  • イントロダクション
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • エンドユーザーセグメント別:市場魅力指数
  • 病院
    • イントロダクション
    • 市場規模分析、および前年比成長分析(2018-2026)
  • クリニック
  • その他

第10章 多形性膠芽腫市場-地域別

  • イントロダクション
    • 地域別:市場規模分析、および前年比成長分析
    • 地域別:市場魅力指数
  • 北米
    • イントロダクション
    • 主要地域ごとの力学
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • 分子タイプ別:市場規模分析、および前年比成長分析
    • 投与経路別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 欧州
    • イントロダクション
    • 主要地域ごとの力学
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • 分子タイプ別:市場規模分析、および前年比成長分析
    • 投与経路別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 南米
    • イントロダクション
    • 主要地域ごとの力学
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • 分子タイプ別:市場規模分析、および前年比成長分析
    • 投与経路別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • アジア太平洋
    • イントロダクション
    • 主要地域ごとの力学
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • 分子タイプ別:市場規模分析、および前年比成長分析
    • 投与経路別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 中東とアフリカ
    • イントロダクション
    • 主要地域ごとの力学
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • 分子タイプ別:市場規模分析、および前年比成長分析
    • 投与経路別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析

第11章 多形性膠芽腫市場の競合情勢状況

    • 競合シナリオ
    • 市場ポジショニング/シェア分析
    • 合併と買収の分析

第12章 多形性膠芽腫の市場企業プロファイル概要

  • Genentech
    • 企業概要
    • 製品ポートフォリオ・概要
    • 要点
    • 財務概要
  • Amgen
  • Merck & Co., Inc
  • Teva Pharmaceutical Industries, Ltd.
  • Arbor Pharmaceuticals LLC
  • Sun Pharmaceutical Industries, Ltd.
  • F. Hoffman-La Roche
  • Novartis AG
  • Pfizer

第13章 多形性膠芽腫市場-重要考察

第14章 多形性膠芽腫市場-Data-M

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次

Market Overview

The Global Glioblastoma Multiforme Market is expected to grow at a high CAGR during the forecasting period (2020-2027).

Glioblastoma multiforme (GBM) is the malignant type of central nervous system tumor. Globally, GBM accounts for 54% of new gliomas and 45% of primary malignant tumors. GBM can be either intra tentorial (area located below tentorium cerebilli) or supra tentorial (area located above the tentorium cerebilli). New treatments are coming forward involving drugs which can be used alone or in combination with radiotherapy and chemotherapy. Still, there are more chances of reappearance when compared with electric field therapy. Increased research and clinical trials in the treatment of GBM through immunotherapy is expected to account for a significant share in the growth of the market.

Market Dynamics

The major driving forces are the increasing number of brain and other nervous system cancers, an increase in funding for companies by the closed-ended competitive companies, promising pipeline, and increasing US FDA approval of new drugs.

Rising incidence of GBM is one of the dominating factors, propelling the global GBM market. According to GLOBOCAN 2018, over 241,000 people die every year as a result of brain or nervous system cancer, where GBM is the most common form of the disease. According to the Global Burden of Diseases, Injuries, and Risk Factors (GBD), in 2016, there were 330 000 incident cases of CNS cancer, with an incidence rate of 4*63 per 100 000 person-years, which significantly has been increased by 17*3% between 1990 and 2016. Thus, the rising number of cases of GBM is expected to drive the GBM market during the forecast period.

An increase in funding for companies by other closed-ended investment companies, for the research on GBM is also contributing to the growth of the market. For instance, in February 2018, Novocure has announced that it has received capital from BioPharma Credit PLC, an investment fund of Pharmakon Advisors, LP. The term loan agreement of 150 million US dollars, will be used by Novocure to accelerate its research and development segment for improving the treatment options of GBM.

An increased number of US FDA approvals is also expected to drive the market during the forecast period. For instance, in December 2017, Genentech announced that it had received approval from the US FDA for Avastin (bevacizumab) for the treatment of glioblastoma in adults. In September 2017, FDA approved Amgen's MVASI (bevacizumab), the first bevacizumab biosimilar, as well as the first anti-cancer biosimilar, which is approved for the treatment of five types of cancer, including GBM.

The promising drug pipeline is expected to boost market growth over the forecast period. For instance,

However, the high expenditure involved in the research, recurrence of GBM, resistance of glioma stem cells against conventional therapies, neurotoxicity caused by commercialized drugs for GBM, along with lack of efficacy of GBM treatment leading to increase in mortality rate may restrain the growth of the market.

The recurrence of GBM is expected to hamper the market growth. For instance, studies have shown that glioblastoma multiforme recurrence mostly occurs in the form of a continuous growth locally within 2-3 cm from the border of the original lesion. Also, more than 90% of patients with glioma will show recurrence at the original tumor location, and the multiple lesions will develop at a 5% rate after the treatment. Secondly, although less common, GBM may also recur through the development of new parenchymal lesions that fail to exhibit continuous growth patterns, intraventricular spread, or dissemination.

Market Segmentation

Based on the treatment type, the global glioblastoma multiforme market is segmented into drugs, electric field therapy, immunotherapy, and others.

The drug segment is expected to grow at a high rate over the period of forecast. Drugs include temozolomide, bevacizumab, carmustine, and others.

Temozolomide is expected to account for significant growth in the market owing to the advantages offered by the drug, which include delayed progression without impacting the quality of life with less adverse effects of the molecule. Also, methylated or alkylated DNA in the structural anomalies of the drug will produce a good efficacy, thus leading to the higher preference of this drug over the other drugs. On the contrary, pipeline drugs are expected to be the fastest-growing segment during the forecast period as a result of the observation of less adverse effects in adult patient base with the use of the available drug options. For instance,

Immunotherapy is expected to grow at a significant rate over the period of forecast. Promising immunotherapeutic drugs in the GBM pipeline is expected to grow at a considerable rate. For instance, Active immunotherapy (vaccine) involves Rindopepimut (Rintega, CDX-110), which is under development by Celldex, a vaccine that is composed of peptides. It is designed to treat patients expressing a mutant of EGFR (EGFRvIII), which is present among 20-30% of GBM patients and is absent from healthy cells. SurVaxM, which is under development by MimiVax, is a peptide vaccine that targets survivin, a protein responsible for glioma cell survival, which is present among 95% of GBM patients.

Electric field therapy is expected to grow at a significant rate over the period of forecast. For instance, researchers of Northwestern University Feinberg School of Medicine in Chicago have found that people suffering from glioblastoma treated with tumor-treating fields (TTFields), a form of electric field therapy in combination with chemotherapy had extended survival rate than the patients who are treated with chemotherapy alone. Results of the study had revealed that the patients treated with TTFields plus temozolomide had an overall survival of 20.9 months compared with those who received temozolomide alone.

Source: DataM Intelligence Analysis (2019)

Based on the type of molecule, the global glioblastoma multiforme market is segmented into small molecules and biologics.

The small molecule segment is expected to grow at a high rate over the forecast period, owing to the presence of ongoing clinical trials on small molecules. For instance,

The biologics segment is expected to grow at a high rate over the forecast period. Biologic products present a unique opportunity for the focal treatment of glioblastoma multiforme. Focal treatment techniques offer a practical and feasible treatment option for those suffering from glioblastoma. With biologics, the focus is on treating the tumor at a cellular or molecular level. These factors together are expected to contribute to the growth of the GBM market over the next few years.

Geographical Analysis

Geographically, the global glioblastoma multiforme market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is expected to contribute to the significant market share in the glioblastoma multiforme market over the forecast period (2020-2027). This is owing to the increasing incidences of the central nervous system cancers in the geriatric population. According to the study done by the National Brain Tumor Society, in 2018, 78,980 new cases of non-malignant, primary malignant, and other central-nervous-system tumors are diagnosed in the US.

However, over the forecast period (2020-2027), the Asia-Pacific is expected to dominate the Global glioblastoma multiforme market. This is owing to the Grant of regulatory approval for new therapies for glioblastoma. The Ministry of Health, Labour, and Welfare of Japan, in December 2017, has given permission for the Central Social Insurance Medical Council for issuing reimbursement for Novocure's Optune, a portable device used for the treatment of newly diagnosed GBM. Japan is expected to share a significant growth in the market over the forecast period. This is owing to the presence of a high number of elderly individuals as the tumor continues to grow increasing with age, peaking between 75 to 84 years of age and then declines after 85 years.

Competitive Landscape

The key players operating in the global glioblastoma multiforme market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., F. Hoffmann-Le Roche AG, Novartis, and Pfizer.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the glioblastoma multiforme market globally. For instance,

On June 28, 2019, Pfizer announced that the US FDA has approved ZIRABEV (bevacizumab), a biosimilar to Avastin (bevacizumab), for the treatment of 5 types of cancer: non-small cell lung cancer (NSCLC) metastatic colorectal cancer, recurrent or metastatic non-squamous, recurrent glioblastoma, metastatic renal cell carcinoma (GBM), and persistent, recurrent or metastatic cervical cancer.

On April 10, 2018, Novartis AG announced that the FDA has approved Afinitor DISPERZ (Everolimus) tablets for oral suspension in adjunctive treatment of adults and pediatric patients of 2 years old.

On May 21, 2018, MimiVax LLC, announced the positive results from a multicenter Phase 2 study of SurVaxM in patients with a newly diagnosed glioblastoma (nGBM). These promising results support further development of SurVaxM in combination with the standard therapy as a potential treatment for glioblastoma multiforme (GBM).

In December 2017, Genentech announced that it had received approval from US FDA for Avastin (bevacizumab) for the treatment of glioblastoma in adults.

In September 2017, the FDA approved Amgen's MVASI (bevacizumab), which is the first bevacizumab biosimilar and the first anti-cancer biosimilar for treating five types of cancer, including GBM.

In July 2016, Mylan had launched Temozolomide capsules, which is a generic version of Merck's Temodar in the U.S. These capsules are indicated for adult patients with glioblastoma multiforme.

Why Purchase the Report?

  • Visualize the composition of the global glioblastoma multiforme market across each treatment type, type of molecule, route of administration, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global glioblastoma multiforme market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global glioblastoma multiforme market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Type mapping in excel for the key Services of all major market players.

The Global Glioblastoma Multiforme Market report would provide access to an approx, 70 market data tables, 63 figures, and 220 pages.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Type Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Glioblastoma Multiforme Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Glioblastoma Multiforme Market - Market Definition and Overview

3. Glioblastoma Multiforme Market - Executive Summary

  • 3.1. Market Snippet by Treatment type
  • 3.2. Market Snippet by Type of molecule
  • 3.3. Market Snippet by Route of administration
  • 3.4. Market Snippet by End-user

4. Glioblastoma Multiforme Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. The rising incidence of glioblastoma multiforme
    • 4.2.2. The promising drug pipeline
  • 4.3. Restraints
    • 4.3.1. The recurrence of glioblastoma multiforme
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Glioblastoma Multiforme Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. Glioblastoma Multiforme Market - By Treatment type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 6.1.2. Market Attractiveness Index, By Treatment type Segment
  • 6.2. Drugs*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    • 6.2.3. Temozolomide
    • 6.2.4. Bevacizumab
    • 6.2.5. Carmustine
    • 6.2.6. Others
  • 6.3. Immunotherapy
  • 6.4. Electric field therapy
  • 6.5. Others

7. Glioblastoma Multiforme Market - By Type of molecule

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of molecule
    • 7.1.2. Market Attractiveness Index, By Type of molecule Segment
  • 7.2. Small molecules*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.3. Biologics

8. Glioblastoma Multiforme Market - By Route of administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 8.1.2. Market Attractiveness Index, By Route of administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.3. Parenteral

9. Glioblastoma Multiforme Market - By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 9.3. Clinics
  • 9.4. Others

10. Glioblastoma Multiforme Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of molecule
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. The U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of molecule
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. The U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of molecule
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of molecule
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. The Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of molecule
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Glioblastoma Multiforme Market Competitive Landscape

    • 11.1.1. Competitive Scenario
    • 11.1.2. Market Positioning/Share Analysis
    • 11.1.3. Mergers and Acquisitions Analysis

12. Glioblastoma Multiforme Market Company Profiles

  • 12.1. Genentech*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Amgen
  • 12.3. Merck & Co., Inc
  • 12.4. Teva Pharmaceutical Industries, Ltd.
  • 12.5. Arbor Pharmaceuticals LLC
  • 12.6. Sun Pharmaceutical Industries, Ltd.
  • 12.7. F. Hoffman-La Roche
  • 12.8. Novartis AG
  • 12.9. Pfizer

13. Glioblastoma Multiforme Market - Premium Insights

14. Glioblastoma Multiforme Market - Data-M

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us